These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 26402079)

  • 1. Plasma Fatty Acid Profiles in Relation to Cognition and Gender in Alzheimer's Disease Patients During Oral Omega-3 Fatty Acid Supplementation: The OmegAD Study.
    Eriksdotter M; Vedin I; Falahati F; Freund-Levi Y; Hjorth E; Faxen-Irving G; Wahlund LO; Schultzberg M; Basun H; Cederholm T; Palmblad J
    J Alzheimers Dis; 2015; 48(3):805-12. PubMed ID: 26402079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Homocysteine Status Modifies the Treatment Effect of Omega-3 Fatty Acids on Cognition in a Randomized Clinical Trial in Mild to Moderate Alzheimer's Disease: The OmegAD Study.
    Jernerén F; Cederholm T; Refsum H; Smith AD; Turner C; Palmblad J; Eriksdotter M; Hjorth E; Faxen-Irving G; Wahlund LO; Schultzberg M; Basun H; Freund-Levi Y
    J Alzheimers Dis; 2019; 69(1):189-197. PubMed ID: 30958356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transfer of omega-3 fatty acids across the blood-brain barrier after dietary supplementation with a docosahexaenoic acid-rich omega-3 fatty acid preparation in patients with Alzheimer's disease: the OmegAD study.
    Freund Levi Y; Vedin I; Cederholm T; Basun H; Faxén Irving G; Eriksdotter M; Hjorth E; Schultzberg M; Vessby B; Wahlund LO; Salem N; Palmblad J
    J Intern Med; 2014 Apr; 275(4):428-36. PubMed ID: 24410954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial.
    Freund-Levi Y; Eriksdotter-Jönhagen M; Cederholm T; Basun H; Faxén-Irving G; Garlind A; Vedin I; Vessby B; Wahlund LO; Palmblad J
    Arch Neurol; 2006 Oct; 63(10):1402-8. PubMed ID: 17030655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms.
    Freund-Levi Y; Basun H; Cederholm T; Faxén-Irving G; Garlind A; Grut M; Vedin I; Palmblad J; Wahlund LO; Eriksdotter-Jönhagen M
    Int J Geriatr Psychiatry; 2008 Feb; 23(2):161-9. PubMed ID: 17582225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects on transthyretin in plasma and cerebrospinal fluid by DHA-rich n - 3 fatty acid supplementation in patients with Alzheimer's disease: the OmegAD study.
    Faxén-Irving G; Freund-Levi Y; Eriksdotter-Jönhagen M; Basun H; Hjorth E; Palmblad J; Vedin I; Cederholm T; Wahlund LO
    J Alzheimers Dis; 2013; 36(1):1-6. PubMed ID: 23563245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lower omega-3 fatty acid intake and status are associated with poorer cognitive function in older age: A comparison of individuals with and without cognitive impairment and Alzheimer's disease.
    Phillips MA; Childs CE; Calder PC; Rogers PJ
    Nutr Neurosci; 2012 Nov; 15(6):271-7. PubMed ID: 22824373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Omega-3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the omega-3 Alzheimer's disease study.
    Irving GF; Freund-Levi Y; Eriksdotter-Jönhagen M; Basun H; Brismar K; Hjorth E; Palmblad J; Vessby B; Vedin I; Wahlund LO; Cederholm T
    J Am Geriatr Soc; 2009 Jan; 57(1):11-7. PubMed ID: 19054188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of supplementation with omega-3 fatty acids on oxidative stress and inflammation in patients with Alzheimer's disease: the OmegAD study.
    Freund-Levi Y; Vedin I; Hjorth E; Basun H; Faxén Irving G; Schultzberg M; Eriksdotter M; Palmblad J; Vessby B; Wahlund LO; Cederholm T; Basu S
    J Alzheimers Dis; 2014; 42(3):823-31. PubMed ID: 24934544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of omega-3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer's disease: the OmegAD study.
    Freund-Levi Y; Hjorth E; Lindberg C; Cederholm T; Faxen-Irving G; Vedin I; Palmblad J; Wahlund LO; Schultzberg M; Basun H; Eriksdotter Jönhagen M
    Dement Geriatr Cogn Disord; 2009; 27(5):481-90. PubMed ID: 19439966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of DHA-rich n-3 fatty acid supplementation on gene expression in blood mononuclear leukocytes: the OmegAD study.
    Vedin I; Cederholm T; Freund-Levi Y; Basun H; Garlind A; Irving GF; Eriksdotter-Jönhagen M; Wahlund LO; Dahlman I; Palmblad J
    PLoS One; 2012; 7(4):e35425. PubMed ID: 22545106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. No Effect of Omega-3 Fatty Acid Supplementation on Cognition and Mood in Individuals with Cognitive Impairment and Probable Alzheimer's Disease: A Randomised Controlled Trial.
    Phillips MA; Childs CE; Calder PC; Rogers PJ
    Int J Mol Sci; 2015 Oct; 16(10):24600-13. PubMed ID: 26501267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study.
    Chiu CC; Su KP; Cheng TC; Liu HC; Chang CJ; Dewey ME; Stewart R; Huang SY
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1538-44. PubMed ID: 18573585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of n-3 fatty acids on cognitive decline: a randomized, double-blind, placebo-controlled trial in stable myocardial infarction patients.
    Geleijnse JM; Giltay EJ; Kromhout D
    Alzheimers Dement; 2012 Jul; 8(4):278-87. PubMed ID: 21967845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of docosahexaenoic acid-rich n-3 fatty acid supplementation on cytokine release from blood mononuclear leukocytes: the OmegAD study.
    Vedin I; Cederholm T; Freund Levi Y; Basun H; Garlind A; Faxén Irving G; Jönhagen ME; Vessby B; Wahlund LO; Palmblad J
    Am J Clin Nutr; 2008 Jun; 87(6):1616-22. PubMed ID: 18541548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DHA-rich n-3 fatty acid supplementation decreases DNA methylation in blood leukocytes: the OmegAD study.
    Karimi M; Vedin I; Freund Levi Y; Basun H; Faxén Irving G; Eriksdotter M; Wahlund LO; Schultzberg M; Hjorth E; Cederholm T; Palmblad J
    Am J Clin Nutr; 2017 Oct; 106(4):1157-1165. PubMed ID: 28855224
    [No Abstract]   [Full Text] [Related]  

  • 17. The effects of long-term omega-3 fatty acid supplementation on cognition and Alzheimer's pathology in animal models of Alzheimer's disease: a systematic review and meta-analysis.
    Hooijmans CR; Pasker-de Jong PC; de Vries RB; Ritskes-Hoitinga M
    J Alzheimers Dis; 2012; 28(1):191-209. PubMed ID: 22002791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Souvenaid on plasma micronutrient levels and fatty acid profiles in mild and mild-to-moderate Alzheimer's disease.
    Rijpma A; Meulenbroek O; van Hees AM; Sijben JW; Vellas B; Shah RC; Bennett DA; Scheltens P; Olde Rikkert MG
    Alzheimers Res Ther; 2015; 7(1):51. PubMed ID: 26213579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: results of the Alzheimer's Disease Cholesterol-Lowering Treatment (ADCLT) trial.
    Sparks DL; Connor DJ; Sabbagh MN; Petersen RB; Lopez J; Browne P
    Acta Neurol Scand Suppl; 2006; 185():3-7. PubMed ID: 16866904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced prostaglandin F2 alpha release from blood mononuclear leukocytes after oral supplementation of omega3 fatty acids: the OmegAD study.
    Vedin I; Cederholm T; Freund-Levi Y; Basun H; Hjorth E; Irving GF; Eriksdotter-Jönhagen M; Schultzberg M; Wahlund LO; Palmblad J
    J Lipid Res; 2010 May; 51(5):1179-85. PubMed ID: 19965584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.